Biocept, Inc. (BIOC) News
Filter BIOC News Items
BIOC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BIOC News From Around the Web
Below are the latest news stories about BIOCEPT INC that investors may wish to consider to help them evaluate BIOC as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the workweek with a detailed breakdown of the biggest pre-market stock movers for Monday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning! |
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesSAN DIEGO, September 21, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept’s proprietary CNSide assay in monitoring the response to therapy of LM, a |
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Benzinga exclusively broke the story. Plus Therapeutics is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal m |
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System CancersPlus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy. Under the terms of the agreement, CNSide developer Biocept has granted Plus Therapeutics a non-exclusive license to its CNSide cell enumeration assay for Plus' investigational therapy for leptomeningeal metastases |
Biocept Signs CNSide™ Licensing Agreement with Plus TherapeuticsSAN DIEGO, September 08, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or |
Biocept to Participate in the H.C. Wainwright Global Investment ConferenceSAN DIEGO, September 05, 2023--Biocept, Inc. (Nasdaq: BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time. |
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot PoleThere are some solid biotech stocks on the market. |
Biocept to Hold Business Update Conference Call on August 30, 2023SAN DIEGO, August 25, 2023--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. |